Key result
Transgenic mouse hearts expressing slow skeletal troponin I showed a significantly blunted increase in Ca2+ sensitivity associated with increased sarcomere length compared to wild-type controls.
Expression of slow skeletal troponin I in mouse hearts blunts the length-dependent increase in Ca2+ sensitivity of myofilaments, providing a basis for testing the significance of length dependence of activation in situ.
Blunts length-dependent Ca2+ sensitization in mouse hearts; leaves open its role in Frank-Starling mechanism in vivo.
We compared sarcomere length (SL) dependence of the Ca2+-force relation of detergent-extracted bundles of fibres dissected from the left ventricle of wild-type (WT) and transgenic mouse hearts expressing slow skeletal troponin I (ssTnI-TG). Fibre bundles from the hearts of the ssTnI-TG demonstrated a complete replacement of the cardiac troponin I (cTnI) by ssTnI. Compared to WT controls, ssTnI-TG fibre bundles were more sensitive to Ca2+ at both short SL (1.9 +/- 0.1 micrometer) and long SL (2.3 +/- 0.1 micrometer). However, compared to WT controls, the increase in Ca2+ sensitivity (change in half-maximally activating free Ca2+; DeltaEC50) associated with the increase in SL was significantly blunted in the ssTnI-TG myofilaments. Agents that sensitize the myofilaments to Ca2+ by promoting the actin-myosin reaction (EMD 57033 and CGP-48506) significantly reduced the length-dependent DeltaEC50 for Ca2+ activation, when SL in WT myofilaments was increased from 1.9 to 2.3 micrometer. Exposure of myofilaments to calmidazolium (CDZ), which binds to cTnC and increases its affinity for Ca2+, sensitized force developed by WT myofilaments to Ca2+ at SL 1.9 micrometer and desensitized the WT myofilaments at SL 2.3 micrometer. There were no significant effects of CDZ on ssTnI-TG myofilaments at either SL. Our results indicate that length-dependent Ca2+ activation is modified by specific changes in thin filament proteins and by agents that promote the actin-myosin interaction. Thus, these in vitro results provide a basis for using these models to test the relative significance of the length dependence of activation in situ.
No takes yet. Share an insight, caveat, or question.
Arteaga et al. (2000) studied this question. Expression of slow skeletal troponin I (ssTnI-TG) vs. Wild-type (WT) controls was evaluated on Sarcomere length dependence of the Ca2+-force relation (change in half-maximally activating free Ca2+; DeltaEC50). Transgenic mouse hearts expressing slow skeletal troponin I showed a significantly blunted increase in Ca2+ sensitivity associated with increased sarcomere length compared to wild-type controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from The Journal of Physiology